Health-care shares flat in pre-market trade Friday.
In health-care stocks news, Acura Pharmaceuticals ( ACUR ) said it will review data from a study on its Aversion drug, which is intended to deter abuse by nasal snorting and injection, to determine whether to continue developing it, after the U.S. Food and Drug Administration questioned the relevance of abuse of hydrocodone with acetaminophen products.
And, Achillion Pharmaceuticals ( ACHN ) has reported 100% of patients treated in its Phase 2 proxy study evaluating ACH-3102 remained HCV RNA undetectable four weeks after completing therapy.
The data were reported as interim results from its ongoing study of ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in a total of 12 patients patients with treatment-naC/ve genotype 1 chronic hepatitis C virus (HCV) infection.
ACHN was up $1.56, or 18.48%, at $10.00 in pre-market trading .
Finally, Skystar Bio-Pharmaceutical ( SKBI ) reported that revenue for Q2 ended June 30, 2014, improved from the comparable quarter the previous year despite a year-over-year decline in earnings, and reiterated its guidance for fiscal 2014.
The China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives posted Q2 earnings of $2.8 million or $0.37 per share, compared with the prior-year period's $3.8 million or $0.49 per share.
Shares closed at $5.40 with a 52-week range of $1.57 - $8.22.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.